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Background: While ovarian cancer is recognised as having identifiable early symptoms, understanding of the key
determinants of symptom awareness and early presentation is limited. A population-based survey of ovarian cancer
awareness and anticipated delayed presentation with symptoms was conducted as part of the International Cancer
Benchmarking Partnership (ICBP).
Methods: Women aged over 50 years were recruited using random probability sampling (n = 1043). Computer-assisted
telephone interviews were used to administer measures including ovarian cancer symptom recognition, anticipated time
to presentation with ovarian symptoms, health beliefs (perceived risk, perceived benefits/barriers to early presentation,
confidence in symptom detection, ovarian cancer worry), and demographic variables. Logistic regression analysis was
used to identify the contribution of independent variables to anticipated presentation (categorised as < 3 weeks or≥
3 weeks).
Results: The most well-recognised symptoms of ovarian cancer were post-menopausal bleeding (87.4%), and persistent
pelvic (79.0%) and abdominal (85.0%) pain. Symptoms associated with eating difficulties and changes in bladder/bowel
habits were recognised by less than half the sample. Lower symptom awareness was significantly associated with older
age (p≤ 0.001), being single (p≤ 0.001), lower education (p≤ 0.01), and lack of personal experience of ovarian cancer
(p≤ 0.01). The odds of anticipating a delay in time to presentation of≥ 3 weeks were significantly increased in women
educated to degree level (OR = 2.64, 95% CI 1.61 – 4.33, p≤ 0.001), women who reported more practical barriers
(OR = 1.60, 95% CI 1.34 – 1.91, p≤ 0.001) and more emotional barriers (OR = 1.21, 95% CI 1.06 – 1.40, p≤ 0.01), and those
less confident in symptom detection (OR = 0.56, 95% CI 0.42 – 0.73, p≤ 0.001), but not in those who reported lower
symptom awareness (OR = 0.99, 95% CI 0.91 – 1.07, p = 0.74).
Conclusions: Many symptoms of ovarian cancer are not well-recognised by women in the general population.
Evidence-based interventions are needed not only to improve public awareness but also to overcome the barriers to
recognising and acting on ovarian symptoms, if delays in presentation are to be minimised.
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Ovarian cancer accounts for 4% of all cancers diagnosed
in women, with over 200,000 new cases each year world-
wide [1] and one year survival lowest for women in the
UK [2]. Low awareness and negative beliefs about cancer
are implicated in delayed presentation of cancer symp-
toms, leading to advanced stage at diagnosis and a lower
chance of survival [3-5]. This may especially be the case
for ovarian cancer, a less common cancer with large
international variations in survival rates [6].
Ovarian cancer is now recognised as having detectable
early symptoms including abdominal distension (bloat-
ing, increased abdominal size), pelvic and/or abdominal
pain, problems with eating (loss of appetite, feeling full
quickly), and frequent urination [7,8]. Symptoms are
recognised to be present in both early and late stage
ovarian cancer, with better prognosis for disease diag-
nosed at an earlier stage [9]. However, women with ovar-
ian cancer may not be aware that their symptoms were
indicative of ovarian cancer and may misattribute them
to irritable bowel syndrome, ageing, stress or other be-
nign causes [9,10]. This knowledge provides the basis for
practitioner guidelines [11,12], risk assessment tools [13]
and information for the public [14-16] aimed at improv-
ing ovarian symptom awareness and earlier presentation.
Most patients with ovarian cancer present initially to
their general practitioner, with around half having had
symptoms for more than one month [17]. No screening
programmes exist for ovarian cancer; however, there are
initiatives to determine whether screening may be effect-
ive, including the US-based Symptom Index in combin-
ation with biomarkers [18-20] and the UK ovarian
cancer screening study which reports in 2015 [21]. Given
the lack of an imminent ovarian screening programme
or opportunities in other parts of the diagnostic pathway
to expedite diagnoses, evidence is needed regarding the
determinants of lower awareness and delay in presenta-
tion to inform interventions aimed at improving early
detection of ovarian cancer. Studies of risk factors for
delayed symptomatic presentation in other cancers have
highlighted a range of barriers including older age
[22-24], lower socio-economic status [25], misinterpret-
ing the seriousness of symptoms [26,27], and fears about
what might be found [3].
The present study carried out as part of the International
Cancer Benchmarking Partnership (ICBP) which was estab-
lished in 2010 to investigate the causes of international vari-
ation in cancer outcomes. We sought to identify levels of
ovarian symptom awareness and demographic risk factors
for lower awareness and anticipated delay in a representa-
tive population sample of women over age 50. This age
group was selected because most cases of ovarian cancer
(> 80%) are diagnosed in the over-50s [28]. In addition, we
examined the effects of health beliefs on anticipated delay,including perceived benefits and barriers to symptomatic
presentation, confidence in detecting symptoms, and per-
ceived risk of ovarian cancer [29-31]. In order to develop
interventions which raise cancer awareness without raising
anxiety, it was also considered important to examine the
potential influence of cancer worry [32]. It was hypothe-
sised that few perceived benefits, more barriers, low confi-
dence, and low worry would be associated with anticipated
delay. Since prospective monitoring of actual symptom
presentation would require following up an unfeasibly large
sample, we used a hypothetical question (“how long it
would take you to go to the doctors with a symptom”) as a
proxy measure of delayed presentation.
Methods
The survey was conducted as a subset of the ICBP sur-
vey of awareness and beliefs about cancer in adults aged
≥50 years in six countries [33]. For the present analyses,
we used data from female respondents in Wales. Ethical
approval was obtained from Cardiff University School of
Medicine Research Ethics Committee. The survey was
carried out by trained interviewers who introduced the
study to eligible individuals and obtained verbal in-
formed consent.
Inclusion/exclusion criteria
Respondents were women aged over 50 years who were
resident in Wales and gave verbal consent. Women were
excluded if they reported having had a personal diagnosis
of ovarian cancer and/or had undergone oophorectomy.
Procedures
Random probability sampling was used to achieve a
population-representative sample using electronic tele-
phone directories as the sampling frame. The final two
digits of each selected telephone number were replaced
with two random numbers, to include numbers that
were not publicly available. Households were eligible if
one or more person was aged 50 or over and spoke Eng-
lish. Where more than one person was eligible, the Rizzo
method was used to randomly select one person to be
interviewed, thereby giving an equal chance of selection
to all eligible people living in the household [34]. Survey
data were collected during May to July 2011 using
computer-assisted telephone interviews. At the end of
the interview, participants were offered contact details of
a local cancer support charity.
Sample size
Assuming a design effect of 1.2 (adjusting for the impact
of the weighting scheme employed), a sub-sample of
1000 women was estimated to provide conservative 95%
confidence intervals of +/−3.7%.
Brain et al. BMC Cancer 2014, 14:171 Page 3 of 10
http://www.biomedcentral.com/1471-2407/14/171Measures
A survey instrument (ABC-O; Awareness and Beliefs
about Cancer-Ovarian) was adapted from the inter-
nationally validated Awareness and Beliefs about Cancer
measure ABC; [35], and the Cancer Awareness Measure
CAM; [36] and its ovarian-specific version [37]. ABC-O
questions were tested for comprehensibility using cogni-
tive interviews (n = 10), for test-retest reliability (n =
100), and for content validity using expert ratings (n = 8)
of relevance and representativeness. Anticipated time to
presentation questions were placed ahead of the symp-
tom recognition question, and the order of all other
questions and response options was rotated randomly.
Major news stories relating to cancer and cancer aware-
ness campaigns were monitored two weeks prior to and
during the survey data collection period. None observed
during this period was related to ovarian cancer symp-
tom awareness.
Ovarian cancer symptom awareness
Eleven statements about recognition of ovarian cancer
symptoms were presented using the question “I’m now go-
ing to list some symptoms that may or may not be warning
signs for ovarian cancer. For each one, can you tell me
whether you think that it could be a warning sign for ovar-
ian cancer?” The list of symptoms included persistent pain
in the abdomen, persistent pain in the pelvis, vaginal bleed-
ing after the menopause, persistent bloating, increased ab-
dominal size, feeling full persistently, difficulty eating,
passing more urine than usual, a change in bowel habits,
extreme tiredness, and back pain (response options were
yes, no, don’t know). Items were adapted from the validated
ovarian CAM [37] and included less common symptoms
(change in bowel habit, fatigue, back pain) to reflect the UK
Department of Health’s ‘Key Messages’ on ovarian cancer
for health professionals and the public [11,15]. The number
of symptoms endorsed was summed (total score range
0–11).
Anticipated delay
An open-ended question was used to assess anticipated
time to symptomatic presentation: “If you had a symptom
that you thought might be a sign of ovarian cancer, please
tell me how long it would take you to go to the doctors
from the time you first noticed the symptom.” Responses
were coded according to a number of predefined categories
(e.g., “I would go as soon as I noticed”, “up to one week”,
“more than a month”). A dichotomous delay variable
(< 3 weeks, > 3 weeks) was created to reflect guidelines re-
garding frequency and persistence of symptoms such as
bloating and pain, and the three week symptom timeline
currently used in the UK ovarian cancer awareness cam-
paign [38]. Sensitivity analyses were used to test effects of
using different delay thresholds (1 and 2 weeks).Health beliefs
Health beliefs included perceived benefits of early symp-
tomatic presentation, emotional barriers to presentation,
practical barriers to presentation, perceived risk, and
confidence in symptom detection. Perceived benefits in-
cluded five items (e.g. “If ovarian cancer is diagnosed
early, it can be treated more successfully”) rated from 1
(strongly disagree) to 4 (strongly agree) with a total pos-
sible score range of 5–20 (Cronbach’s α = 0.71). Four
items measured emotional barriers (e.g. “I would be too
scared”, score range 4–12, α = 0.68). Three items mea-
sured practical barriers (e.g. “I would be too busy to
make time to go to the doctor”, score range 3–9, α =
0.60). Response options for the barriers items were 1 =
yes, often, 2 = yes, sometimes, and 3 = no (reverse
scored). Perceived risk was a single item adapted from
previous research [39], with response options from 1
(much more likely to get it) to 5 (much less likely to get
it) recoded so that a higher score indicated higher per-
ceived risk. Confidence in symptom detection was mea-
sured by asking respondents “How confident, or not, are
you that you would notice a symptom of ovarian can-
cer?” (1 = not at all confident and 4 = very confident).
Cancer worry
The Ovarian Cancer Worry Scale [40] included three items
regarding the frequency of worry (“How often do you worry
about getting ovarian cancer someday?”), and the impact of
worry on mood (“How often, if at all, does your worry
about getting ovarian cancer someday affect your mood?”)
and functioning (“How often, if at all, does your worry
about getting ovarian cancer someday affect your ability to
perform your daily activities?”). Items were rated from 1
(not at all) to 5 (almost all the time), with a score range 1–
15 (α = 0.69). Scores were log transformed due to non-
normal distribution (floor effect).
Demographic variables included age, ethnicity, level of
education, socioeconomic status (Welsh Index of Mater-
ial Deprivation score), relationship status, and experi-
ence of ovarian cancer diagnosed in family members or
friends.
Statistical analysis
Survey response rate was calculated using the American
Association for Public Opinion Research (AAPOR) con-
ventions, because the denominator of eligible people was
unknown and therefore response rate could not be cal-
culated in the usual way [41]. The ‘minimum response
rate’ was conservatively calculated as the number of
complete interviews divided by the number of all pos-
sible interviews (the number of interviews among eli-
gible people plus the number of households where
eligible people were known to live, but where the inter-
view could not be completed (e.g. refusal, interview
Table 2 Sample characteristics (N = 1043)
Variable Descriptive statistic
Age, years n (%)
50-59 348 (33.4%)
60-69 387 (37.0%)
70+ 300 (28.8%)
Missing 8 (0.8%)
Ethnic background n (%)
White ethnicity 1031 (98.8%)
Other ethnicity 11 (1.1%)
Missing 1 (0.1%)
Relationship status n (%)
Married or cohabiting 515 (49.4%)
Not married or cohabiting 525 (50.3%)
Missing 3 (0.3%)
Education n (%)
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known eligibility). It represents the response rate assum-
ing that all households that we could not assess for
eligibility were eligible (equivalent to AAPOR response
rate formula 1). It is likely to underestimate response
rates because it is likely that many households were in-
eligible. We also calculated the ‘estimated response rate’
as the number of completed interviews divided by the
estimated number of eligible individuals, based on the
proportion of households that were eligible out of those
assessed for eligibility (equivalent to AAPOR response
rate formula 3).
Associations between demographic variables and ovar-
ian symptom awareness were examined using appropri-
ate univariate analyses. Preliminary associations between
anticipated delay and demographic variables, symptom
awareness, health beliefs and cancer worry were tested
using chi square or independent t-tests, with variables
significant at p ≤ 0.01 subsequently entered into a logistic
regression model. Results are presented for both un-
adjusted data and data adjusted for sample non-
representativeness in age, region, relationship status and
education. Sensitivity analyses were undertaken at each
stage to test for effects of under-representation of cer-
tain demographic groups.Table 1 Overall response rate
N
Total number of households with connected telephone
numbers approached
26,262
Number of households of unknown eligibility* 18,210
Number of households of known eligibility 8,052
Number of households in which the individual declined to take
part either during or after assessment of eligibility
1,294
Number of ineligible households* 4,283
Number of eligible households* 3,769
Proportion of households eligible among those assessed for
eligibility (%)
46.8
Completed interviews 2,298
Minimum response rate (%)† 10.5
Estimated response rate (%)** 46.8
*A household was eligible if one or more people aged 50+ lived in
the household.
†The minimum response rate represents the response rate assuming all
households that we could not assess for eligibility were eligible, in other
words the lowest possible response rate. It is calculated as the number of
completed interviews divided by the number of all possible interviews, i.e. the
number of interviews among eligible people plus the number of incomplete
interviews among eligible people (refusals, break-offs and non-contacts) plus
the number of all households of unknown eligibility (equivalent to the
American Association for Public Opinion Research response rate formula 1).
**The estimated response rate represents the response rate after adjusting the
size of the denominator for the likely proportion of households that were
eligible. It is calculated by assuming that the proportion eligible among
households of unknown eligibility is the same as the proportion of those
tested for eligibility who were eligible (equivalent to American Association for
Public Opinion Research response rate formula 3).Results
Sample characteristics
The overall study response rate was 2298 eligible men
and women completing the larger ABC survey in Wales
(Table 1). The minimum response rate was 10.5% be-
cause the number of households for which we did notUp to 16 years 570 (54.7%)
Secondary 254 (24.4%)
Degree and above 197 (18.9%)
Missing 22 (2.0%)
Socioeconomic status
First quartile (most deprived) 178 (17.1%)
Second quartile 246 (23.6%)
Third quartile 229 (22.0%)
Fourth quartile (least deprived) 253 (24.3%)
Missing 137 (13.0%)
Experience of ovarian cancer n (%)
Experience of ovarian cancer 238 (22.8%)
No experience of ovarian cancer 800 (76.7%)
Missing 5 (0.5%)
Anticipated delay n (%)
I would go as soon as I noticed 507 (48.6%)
Up to one week 239 (22.9%)
Over 1 up to 2 weeks 101 (9.7%)
Over 2 up to 3 weeks 51 (4.9%)
Over 3 up to 4 weeks 57 (5.5%)
More than a month 43 (4.1%)
I would not contact my doctor 8 (0.8%)
I would go to a nurse instead of my doctor1 3 (0.3%)
Missing 34 (3.3%)
1Coded as missing.
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dialling. The estimated response rate was 46.8%.
It was not possible to determine the number of eligible
women: of the 2298 survey respondents, 1385 respon-
dents were female. A total 315 women (26%) were ex-
cluded due to a personal medical history of ovarian
cancer (n = 19) or oophorectomy (n = 296). The final
sample was 1043.
As shown in Table 2, most respondents were aged over
60 years and of white ethnicity. Half the sample was not
married or cohabiting, more than half had been educated
up to 16 years only, and almost a quarter had experience of
ovarian cancer. Most women anticipated presenting within
one week of noticing a potential ovarian symptom.
Ovarian symptom awareness levels
As shown in Figure 1, the most well recognised symp-
toms were post-menopausal vaginal bleeding (87.4%),
abdominal pain (85.0%), and pelvic pain (79.0%). More
than half the sample was able to recognise abdominal
bloating (71.7%), increased abdominal size (69.4%), back
pain (68.3%) and tiredness (59.1%). The least recognised
symptoms included a change in bowel habits (49.0%),
feeling full quickly (47.7%), difficulty eating (36.3%), and
a change in bladder habits (32.0%). The mean symptom
recognition score was 6.85 (SD 2.73, range 0–11).
Risk factors for low ovarian symptom awareness
There was a significant effect of age on symptom aware-
ness (p ≤ 0.001), indicating that awareness was signifi-
cantly lower in participants aged 70+ compared to those
aged 50–59 and 60–69 (Table 3). Participants who were
not married/cohabiting (p ≤ 0.001), educated up to0
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Figure 1 Recognition of individual ovarian cancer symptoms.16 years (p ≤ 0.01), and without experience of ovarian
cancer (p ≤ 0.01) reported lower awareness. There was a
marginal effect of lower socioeconomic status (p ≤ 0.05).
The association between awareness and anticipated delay
was not significant. A similar pattern of results was ob-
served after adjusting for sample non-representativeness;
however, the relationship between lower awareness
and anticipated delay reached statistical significance
(p ≤ 0.01).
Risk factors for anticipated delay
Table 4 displays preliminary associations between inde-
pendent variables and anticipated delay. Women in the
50–59 age group (p ≤ 0.01) and those educated to degree
level (p ≤ 0.001) were significantly more likely to antici-
pate waiting at least three weeks. Anticipated delay was
significantly associated with reporting more emotional
barriers (p ≤ 0.001), more practical barriers (p ≤ 0.001),
and lower confidence in symptom detection (p ≤ 0.001).
There were no significant effects of relationship status,
socioeconomic status, ovarian cancer experience, cancer
worry, perceived risk, or perceived benefits of early pres-
entation. Analyses were repeated after weighting for
non-representativeness, with little observed difference
other than cancer worry reaching marginal significance
(p ≤ 0.05).
Statistically significant variables were modelled to deter-
mine their effects on anticipated delay. As shown in Table 5,
the full model was statistically significant (χ2 (6) = 107.61,
p ≤ 0.001) and explained 11% – 22% of the variance in an-
ticipated delay, correctly classifying 89% of cases. The
strongest determinant of anticipated delay was being edu-
cated to degree level (OR = 2.64, p ≤ 0.001). Women who
reported more practical barriers (OR = 1.60, p ≤ 0.001), lessymptom
Yes
No
Table 3 Risk factors for low ovarian symptom awareness
Mean (sd) number of ovarian symptoms recognised out of 11
Unadjusted Statistic Adjusted1 Statistic
Age groups
50-59 years 7.06 (2.61) F (2, 1032) = 10.18, p = 0.000*** 7.23 (2.62) F (2, 1018) = 16.93, p = 0.000***
60-69 years 7.13 (2.61) 7.00 (2.65)
70+ years 6.27 (2.92) 6.08 (2.94)
Ethnic background
White ethnicity 6.85 (2.74) ^ 6.73 (2.80) ^
Other ethnicity 7.18 (2.36) 6.86 (2.41)
Relationship status
Married or cohabiting 7.16 (2.56) t (1038) = 3.65, p = 0.000*** 7.08 (2.61) t (1025) = 4.41, p = 0.000***
Not married or cohabiting 6.55 (2.86) 6.30 (2.97)
Education
Up to 16 years 6.58 (2.81) F (2, 1018) = 6.34, p = 0.002** 6.49 (2.85) F (2, 1005) = 8.23, p = 0.000***
Secondary 7.16 (2.58) 7.08 (2.60)
Degree and above 7.21 (2.57) 7.37 (2.56)
Socioeconomic status
First quartile (most deprived) 6.39 (2.75) F (3,902) = 2.82, p = 0.04* 6.29 (2.74) F (3,886) = 2.82, p = 0.03*
Second quartile 7.07 (2.68) 7.02 (2.72)
Third quartile 7.10 (2.74) 6.85 (2.84)
Fourth quartile (least deprived) 6.87 (2.65) 6.56 (2.86)
Experience of ovarian cancer
Experience of ovarian cancer 7.23 (2.52) t (1036) = 2.51, p = 0.01** 7.32 (2.43) t (1021) = 3.84, p = 0.000***
No experience of ovarian cancer 6.75 (2.78) 6.59 (2.86)
Anticipated delay
Up to three weeks 6.99 (2.67) t (1004) = 1.57, p = 0.12 6.90 (2.75) t (993) = 0.27, p = 0.006**
More than three weeks 6.56 (2.83) 6.11 (2.83)
*p ≤ .05, **p ≤ .01, *** p ≤ .001, ^ sample size not large enough in some cells to conduct statistical tests.
F = ANOVA, t = independent t-test, r = Pearson’s correlation.
1Adjusted for sample non-representativeness in age, education, region, and relationship status.
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and more emotional barriers (OR = 1.21, p ≤ 0.01) were
more likely to anticipate waiting at least three weeks. Nei-
ther age nor ovarian symptom awareness showed a statisti-
cally significant association with anticipated delay.
Repeating the regression analysis on the weighted data
had little effect. The full model was statistically significant
(χ2 (6) = 124.31, p ≤ 0.001) and explained 13% – 26% of the
variance in anticipated presentation, correctly classifying
90% of cases. The pattern of significant determinants
remained the same. In addition, sensitivity analyses con-
firmed the use of a three week threshold to reflect antici-
pated delay.Discussion
Once known as “the silent killer”, ovarian cancer is increas-
ingly recognised as having identifiable early symptoms.However, until an effective method of ovarian screening is
found, women’s prompt help-seeking when they have a po-
tential symptom remains an important avenue to early de-
tection. This population-based survey found that many
symptoms of ovarian cancer were not well recognised by
women in the general population. Ovarian symptoms asso-
ciated with pain, bloating and abnormal bleeding were bet-
ter recognised than those associated with eating difficulties
and changes in bowel and bladder habits. Accurate recogni-
tion may be especially difficult due to the vague and non-
specific nature of some ovarian cancer symptoms, which
may be mistaken for benign conditions [10]. In addition,
awareness of ovarian cancer symptoms was not strongly re-
lated to anticipated delay. The marginal association that
was observed between symptom awareness and anticipated
delay in the present context may reflect the ambiguity of
many early symptoms of ovarian cancer. Improving public
awareness of potential early symptoms could contribute to
Table 4 Preliminary analysis of risk factors for anticipated delay
<3 weeks >3 weeks <3 weeks >3 weeks
(n = 898) (n = 108) (n = 894) (n = 100)
Unadjusted Statistic Adjusted1 Statistic
Age groups n (%)
50-59 years 287 (84) 53 (16) χ2 (2) = 13.36, p = 0.01** 299 (86) 48 (14) χ2 (2) = 9.20, p = 0.01**
60-69 years 337 (90) 36 (10) 265 (90) 28 (10)
70+ years 266 (93) 19 (7) 322 (93) 24 (7)
Ethnic background n (%)
White ethnicity 888 (89) 106 (11) ^ 884 (90) 97 (10) ^
Other ethnicity 9 (82) 2 (18) 9 (75) 3 (25)
Relationship status n (%)
Married or cohabiting 450 (90) 49 (10) χ2 (1) = 0.74, p = 0.39 498 (91) 52 (10) χ2 (1) = 0.39, p = 0.53
Not married or cohabiting 445 (88) 59 (12) 394 (89) 48 (11)
Education n (%)
Up to 16 years 502 (92) 46 (8) χ2 (2) = 18.59, p = 0.000*** 613 (92) 52 (8) χ2 (2) = 25.75, p = 0.000***
Secondary 223 (90) 24 (10) 135 (91) 14 (9)
Degree and above 152 (80) 37 (20) 125 (79) 34 (21)
Socioeconomic status
First quartile (most deprived) 156 (91) 15 (9) χ2 (3) = 3.75, p = 0.29 176 (92) 16 (8) χ
2
(3) = 6.73, p = 0.08
Second quartile 215 (91) 21 (9) 219 (93) 16 (7)
Third quartile 207 (92) 18 (8) 198 (90) 22 (10)
Fourth quartile (least deprived) 211 (87) 31 (13) 181 (86) 29 (14)
Experience of ovarian cancer n (%)
Experience of ovarian cancer 201 (87) 29 (13) χ2 (1) = 1.02, p = 0.31 191 (88) 26 (12) χ2 (1) = 1.05, p = 0.31
No experience of ovarian cancer 694 (90) 77 (10) 699 (91) 72 (9)
Ovarian cancer worry m (sd) 1.31 (0.32) 1.28 (0.27) t (1002) = 0.94, p = 0.35 1.31 (0.33) 1.24 (0.24) t (991) = 1.99, p = 0.05*
Health beliefs m (sd)
Perceived susceptibility 2.43 (0.95) 2.29 (0.97) t (913) = 1.43, p = 0.15 2.38 (0.98) 2.23 (0.93) t (896) = 1.48, p = 0.14
Perceived benefits 17.29 (2.27) 17.11 (2.42) t (846) = 0.74, p = 0.46 17.24 (2.33) 16.96 (2.65) t (808) = 1.07, p = 0.29
Perceived emotional barriers 4.67 (1.25) 5.43 (1.94) t (989) = −3.96, p = 0.000*** 4.72 (1.30) 5.67 (2.11) t (976) = −4.32, p = 0.000***
Perceived practical barriers 3.39 (0.86) 4.40 (1.61) t (1000) = −6.38, p = 0.000*** 3.42 (0.92) 4.50 (1.67) t (989) = −6.58, p = 0.000***
Confidence in symptom detection 2.44 (0.91) 1.86 (0.76) t (980) = 7.30, p = 0.000*** 2.46 (0.93) 1.77 (0.70) t (959) = 8.89, p = 0.000***
*p ≤ .05, **p ≤ .01, ***p ≤ .001, ^ sample size not large enough in some cells to conduct statistical tests.
χ2 = chi square test, t = independent t test.
1 Adjusted for sample non-representativeness in age, education, region, and relationship status.
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evidence and consensus regarding what symptom informa-
tion and guidance should be provided to the public.
Factors associated with poorer recognition of ovarian
symptoms included older age, being single, lower educa-
tional level, and lack of personal experience of the con-
dition. Similarly, Grunfeld et al. [23] found that women
aged over 65 had low knowledge of breast symptoms
and lower perceived risk of breast cancer compared to
younger women. The risk of developing ovarian cancer
increases with age, yet poor knowledge and absence of
concern about ovarian cancer may mean that symptomsexperienced by older women are attributed to other
causes such as the menopause or ageing process, rather
than recognised as a potential threat to health. This may
especially be the case for older women who lack a
spouse or confidante with whom to disclose symptoms
[22,24]. Educational initiatives could therefore target
public understanding of the age/risk association for
ovarian cancer.
In contrast to the findings for awareness, the strongest
risk factor for anticipated delay was higher education.
Other important determinants of delay included lack of
confidence in detecting ovarian cancer symptoms,
Table 5 Logistic regression predicting the likelihood of anticipated delay (< / > 3 weeks)
Unadjusted Adjusted1
Lower Upper Lower Upper
Variables B (SE) p OR 95% CI 95% CI B (SE) p OR 95% CI 95% CI
Age (0 = 60+, 1 = 50-59) 0.31 (0.24) 0.20 1.36 0.86 2.15 0.07 (0.26) 0.80 1.07 0.64 1.79
Education (0 = up to degree, 1 = degree+) 0.97 (0.25) ≤.001 2.64 1.61 4.33 1.34 (0.28) ≤.001 3.83 2.21 6.64
Ovarian cancer symptom awareness (0–11) −0.02 (0.04) 0.74 0.99 0.91 1.07 −0.07 (0.04) 0.11 0.93 0.85 1.02
Practical barriers (3–9) 0.47 (0.09) ≤.001 1.60 1.34 1.91 0.43 (0.09) ≤.001 1.54 1.29 1.83
Emotional barriers (4–12) 0.19 (0.07) ≤.01 1.21 1.06 1.40 0.23 (0.07) ≤.001 1.26 1.10 1.46
Confidence (1–4) −0.59 (0.14) ≤.001 0.56 0.42 0.73 −0.70 (0.15) ≤.001 0.50 0.37 0.68
OR = odds ratio, CI = confidence interval.
1Adjusted for sample non-representativeness in age, education, region, and relationship status.
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ing to waste the doctor’s time, and emotional factors
such as fear and embarrassment. These finding highlight
the importance of a range of psychological, social and
behavioural barriers that may impede the decision to act
on a suspected symptom. Beliefs about self-care, down-
playing potentially serious symptoms, and waiting to see
if symptoms resolve by themselves are important bar-
riers to prompt presentation [26]. Similarly, Scott et al.
[42] found that procrastinating about help-seeking for
oral cancer symptoms was strongly linked to competing
priorities and concerns about the consultation, such as
fear of consequences and not wanting to bother the doc-
tor. The finding regarding educational level contrasts
with reported associations between lower education and
delayed presentation for breast and colon cancer [25],
but mirrors the findings of Low et al. [43]. Further quali-
tative research may help to understand the links between
higher education and perceived barriers to presentation
with ovarian symptoms, in particular the perception of
time-wasting. Improving women’s confidence may be ne-
cessary to bridge the gap between ovarian cancer symp-
tom awareness and earlier presentation, for example by
providing an explicit action plan that describes how and
when to act on potential ovarian symptoms [20,42,44],
including timely follow-up investigations and onward re-
ferrals [45,46] based on clinical consensus regarding
ovarian symptom duration and threshold.
Health beliefs relating to perceived benefits of early pres-
entation were not statistically associated with symptom
awareness or anticipated delay. Overall, women perceived
their risk of ovarian cancer to be average/low and held posi-
tive beliefs, reflecting the overall lack of concern about
ovarian cancer within a population sample. While a moder-
ate amount of concern or worry may have a beneficial role
in prompting health behaviour [47], it was not possible to
test this due to floor effects (i.e. very low worry scores).
Comparison with women at increased risk due to a family
history of ovarian cancer would help to illuminate the role
of emotions in appraising and acting on ovarian symptoms.The hypothetical nature of the health threat and cross-
sectional design are potential limitations of the current
study. Since intentions do not always translate into actual
help-seeking behaviour [48], the relationship between can-
cer symptom awareness and actual presentation would
ideally be tested in large-scale prospective studies [49,50].
The limited association that was found between ovarian
symptom awareness and anticipated delay contrasts with
Robb et al. [3], who found a modest significant association
between higher recognition of general cancer symptoms
and shorter anticipated presentation. This may reflect the
use of an aggregated ovarian symptom recognition measure
in the current study, which may have diluted any effects of
specific symptom recognition [51]. With a larger sample, it
may be possible to test whether recognition of specific
ovarian symptoms such as pain, bloating and abnormal
bleeding reduces the risk of delayed presentation [22,27].
Conclusions
Many ovarian symptoms were not well recognised by
women in the general population. Risk factors for de-
layed presentation included higher education, perceived
barriers, and low confidence in detecting ovarian cancer
symptoms. Further clinical research is needed to develop
evidence-informed ovarian cancer early diagnosis strat-
egies and action plans, and to inform the nuances of the
ovarian cancer symptom message. Interventions could
attempt to overcome the barriers to timely symptomatic
presentation, for example by improving public under-
standing of the age/risk association for ovarian cancer
and improving women’s confidence in their personal
abilities to recognise and act upon ovarian symptoms.
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